Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA versus DARVON COMPOUND 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA versus DARVON COMPOUND 65.
ANEXSIA vs DARVON COMPOUND-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
DARVON COMPOUND-65 contains propoxyphene, a centrally acting opioid agonist with analgesic effects primarily mediated through mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant with additive analgesic effects.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
1 capsule (propoxyphene HCl 65 mg, aspirin 389 mg, caffeine 32.4 mg) orally every 4 hours as needed for pain; maximum 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Propoxyphene: 6-12 hours (mean 8 h); nordextropropoxyphene: 22-30 hours (accumulates with repeated dosing; risk of toxicity)
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Renal: ~90% as propoxyphene and metabolites (nordextropropoxyphene); biliary/fecal: ~10%
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination